Engineering Nanobodies As Lifesavers When SARS-CoV-2 Variants Attack

In lab, molecules inhibit effectively, access nooks too small for human antibodies
Ohio State University
22-Jun-2021 8:30 AM EDT, by Ohio State University

Newswise — COLUMBUS, Ohio – Scientists are pursuing a new strategy in the protracted fight against the SARS-CoV-2 virus by engineering nanobodies that can neutralize virus variants in two different ways.

In lab studies, researchers identified two groups of molecules that were effective against virus variants. Using different mechanisms, nanobodies in each group bypassed mutations and disabled the virus’s ability to bind to the receptor that lets it enter host cells. 

Though vaccination is enabling the resumption of some pre-pandemic activities in parts of the world, SARS-CoV-2 is rapidly working its way around vaccines by mutating itself. In this study, the nanobodies neutralized three emerging variants: Alpha, Beta and Gamma. 

“Companies have already started introducing the variants of concern into the construct of booster shots of the existing vaccines,” said Kai Xu, assistant professor of veterinary biosciences at The Ohio State University and a co-lead author of the research. “But the virus is constantly mutating, and the speed of mutation may be faster than we can capture. Therefore, we need to utilize multiple mechanisms to control the virus spread.”

An accelerated article preview of the study is published online in Nature.

Nanobodies are antibodies derived from immunization of camelid mammals – such as camels, llamas and alpacas – that can be re-designed into tiny molecules that mimic human antibody structures and functions.

For this work, the researchers immunized llamas to produce single-chain antibodies against SARS-CoV-2. They also immunized “nanomice,” transgenic mice with a camelid gene that had been engineered by research fellow Jianliang Xu in the lab of Rafael Casellas, senior investigator at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), to generate nanobodies similar to those produced by camelids.

The team enhanced the nanobodies’ power by immunizing the animals first with the receptor binding domain (RBD), a part of the viral surface spike protein, and following with booster shots containing the entire spike protein.

“By using this sequential immunization strategy, we generated nanobodies that can capture the virion by recognizing the receptor binding domain with very high affinity,” Xu said.

The scientists tested different nanobodies’ neutralization capacity, mapping the surface of the RBD, conducting functional and structure analyses, and measuring the strength of their affinity to narrow the candidate molecules from a large library to six.

The coronavirus is highly infectious because it binds very tightly to the ACE2 receptor to gain access to lung and nasal cavity cells in humans, where it makes copies of itself to infect other cells. The receptor binding domain on the spike protein is fundamental to its success in attaching to ACE2.

“That RBD-ACE2 interface is on the top of the receptor binding domain – that region is the primary target for the protective human antibodies, generated by vaccination or previous infection, to block the viral entry,” Xu said. “But it is also a region frequently mutated in the variants.”

The way mutants have emerged so far suggests long-term reliance on current vaccines will eventually be compromised, the researchers say, because antibody effectiveness is affected significantly by those mutants at the interface.

“We found that certain nanobodies can recognize a conserved region of the receptor binding domain, a hidden location that is too narrow for human antibodies to reach,” Xu said. And attaching at this location, even though it is some distance away from where RBD connects to ACE2, still accomplishes what is intended – blocking SARS-CoV-2 from entering a host cell.

The other group of nanobodies, attracted to the RBD-ACE2 interface, while in their original form could not neutralize certain variants. However, when the researchers engineered this group to be homotrimers – three copies linked in tandem – the nanobodies achieved potent neutralization of the virus. Altering the structure of the nanobodies that attached to the conserved region of RBD in the same way enhanced their effectiveness as well.

There is much more research ahead, but the findings suggest nanobodies could be promising tools to prevent COVID-19 mortality when vaccines are compromised, Xu said.

“Our future plan is to further isolate antibodies specifically against emerging variants for therapeutic development, and to find a better solution for vaccines by learning from those antibodies,” he said.

An HIV vaccine researcher at the NIH before joining Ohio State, Xu collaborated with multiple labs on this research. Jianliang Xu and Rafael Casellas of NIAMS, and Peter Kwong of the National Institute of Allergy and Infectious Diseases (NIAID), are also equal contributors on the study. In addition to numerous NIH agencies, co-author institutions include Rockefeller University, the Aaron Diamond AIDS Research Center at Columbia University and the Frederick National Laboratory for Cancer Research.

This work was supported by NIAMS, the National Cancer Institute, NIH Helix Systems, NIAID and the Frederick National Laboratory for Cancer Research.






Filters close

Showing results

110 of 6101
Released: 30-Jul-2021 2:05 PM EDT
Thinking Impaired in 60% of COVID-19 Survivors, Study Finds
University of Texas Health Science Center at San Antonio

In a sample of over 400 older adults in Argentina who had recovered from COVID-19, more than 60% displayed some degree of cognitive impairment, a researcher from The University of Texas Health Science Center at San Antonio reported July 29 at the Alzheimer’s Association International Conference.

Released: 30-Jul-2021 11:50 AM EDT
Support for Government Mandates High and Increasing Over Time, Survey Finds
Rutgers University-New Brunswick

As the coronavirus Delta variant surges throughout the country and mask and vaccine mandates are being considered, a new national survey finds that almost 20 percent of Americans say it is unlikely that they will get the COVID-19 vaccine.

Newswise: How to Play with Your Children in Age-appropriate and Creative Ways When Schools Are Still Closed and Everyone Is Still Stuck at Home
Released: 30-Jul-2021 8:55 AM EDT
How to Play with Your Children in Age-appropriate and Creative Ways When Schools Are Still Closed and Everyone Is Still Stuck at Home
Chulalongkorn University

The COVID-19 situation may have restricted people’s space, but not their imagination. A Chula lecturer has given recommendations to parents who need to spend more time at home on select social activities to enhance children’s development in a safe and age-appropriate way.

Released: 30-Jul-2021 8:30 AM EDT
American Society of Anesthesiologists Strongly Encourages all Health Care Personnel to Get Vaccinated Against COVID-19
American Society of Anesthesiologists (ASA)

Amid the new surge of COVID-19 cases across the U.S., the American Society of Anesthesiologists (ASA), and eight professional societies associated with the specialty, are strongly encouraging the nation’s health care workers and all eligible Americans to get fully vaccinated with one of the COVID-19 vaccines. ASA and the associated societies remind the public that widespread vaccination is the most effective way to reduce illness and death.

Released: 29-Jul-2021 4:45 PM EDT
Which Voices Led Medical Misinformation in the Early Stages of COVID?
University of Cincinnati

In the early and thus far most devastating stages of the COVID-19 pandemic, scientists were at a near loss on how to treat the deadly disease.

Released: 29-Jul-2021 4:40 PM EDT
Half of U.S. Parents May Not Vaccinate Their Youngest Child Against COVID-19
CUNY Graduate School of Public Health and Health Policy

Even as the delta variant of Covid-19 sweeps the globe, leaving those who remain unvaccinated vulnerable, vaccination among adults and teenagers in the United States is stalling, giving rise to concerns over whether parents will vaccinate their young children once vaccines are approved for those under 12 years of age.

Newswise: COVID-19 update: coping with increased cases, breakthrough infections, national masking mandates and vaccine requirements
Released: 29-Jul-2021 4:05 PM EDT
COVID-19 update: coping with increased cases, breakthrough infections, national masking mandates and vaccine requirements
Keck Medicine of USC

Keck Medicine of USC experts speak out on the continued physical and emotional consequences of COVID-19

Released: 29-Jul-2021 3:45 PM EDT
FSMB: Spreading COVID-19 Vaccine Misinformation May Put Medical License at Risk
Federation of State Medical Boards (FSMB)

The Federation of State Medical Boards’ Board of Directors released statement in response to a dramatic increase in the dissemination of COVID-19 vaccine misinformation and disinformation by physicians and other health care professionals on social media platforms, online and in the media.

Newswise: Argonne’s Macal named Fellow of the Society for Computer Simulation International
Released: 29-Jul-2021 2:05 PM EDT
Argonne’s Macal named Fellow of the Society for Computer Simulation International
Argonne National Laboratory

Charles M. “Chick” Macal, a modeling and simulation expert at Argonne, garnered the distinguished title of Fellow of the Society for Computer Simulation International for his 20 years in the field and his recent studies on COVID-19 spread.

Showing results

110 of 6101